ALK and non-small cell lung carcinoma: Recently, the CROWN trial (NCT03052608), an international randomized phase III trial comparing lorlatinib with crizotinib in patients with previously untreated advanced ALK+ NSCLC, indicated that lorlatinib was associated with a significantly longer PFS, better quality of life (QoL), and a higher intracranial response rate (28).